Advertisement

Topics

A Study to Evaluate and Compare the Effects of Two Approved Drugs in Women With Postmenopausal Osteoporosis

2014-08-27 03:54:04 | BioPortfolio

Summary

This study is to evaluate and compare the effects of two approved medications to treat women with postmenopausal osteoporosis.

Study Design

Allocation: Randomized, Control: Active Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Conditions

Postmenopausal Osteoporosis

Intervention

MK0217, alendronate sodium/Duration of Treatment: 12 mo, Comparator: risedronate/Duration of Treatment: 12 mo

Status

Completed

Source

Merck

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:54:04-0400

Clinical Trials [3205 Associated Clinical Trials listed on BioPortfolio]

A Study to Evaluate the Safety and Tolerability of MK0217 in Women

This study is to assess the safety and tolerability of MK0217 being evaluated to treat women with postmenopausal osteoporosis.

Upper GI Handling of Branded vs. Generic Alendronate

To compare upper GI handling of fosamax and generic, because the main AE profile of alendronate is before systemic absorption in the esophagus; differences could be relevant to the side ef...

FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051)

This study was conducted among women who had previously received alendronate for 3 to 6 years during the Fracture Intervention Trial (FIT). Participants in the FLEX study were randomly ass...

A Study to Compare the Efficacy of Alendronate With and Without Calcium or Calcium Alone In the Treatment of Osteoporosis in Postmenopausal Women

The purpose of this study is to see how well alendronate and calcium as compared to calcium alone increase bone density in postmenopausal women with osteoporosis

A Study to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis

The purpose of this study is to evaluate the effects of two investigational drugs on osteoporosis in postmenopausal women.

PubMed Articles [19436 Associated PubMed Articles listed on BioPortfolio]

A randomized clinical trial of the effectiveness of 0.018-inch and 0.022-inch slot orthodontic bracket systems: part 1-duration of treatment.

To compare treatment duration between 0.018-inch and 0.022-inch slot systems and determine factors influencing treatment duration.

Does the Duration of Fixed Orthodontic Treatment Affect Caries Activity among Adolescents and Young Adults?

This cross-sectional study assessed the relationship between fixed orthodontic treatment duration and caries activity. Two hundred and sixty 10- to 30-year-olds were divided into 4 groups (n = 65): no...

The Association between Sleep Duration and 25-Hydroxyvitamin D Concentration with Obesity in an Elderly Korean Population: A Cross-Sectional Study.

Studies have recently reported an association between sleep duration and obesity in some individuals. Vitamin D deficiency is common in elderly populations and is also associated with obesity. In this...

Duration of active psychosis and functional outcomes in first-episode non-affective psychosis.

The duration of untreated psychosis (DUP) has been associated with negative outcomes in psychosis; however, few studies have focused on the duration of active psychotic symptoms after commencing treat...

Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.

The antiresorptive potency varies between different bisphosphonates. We investigated the effect of stopping oral bisphosphonate treatment for postmenopausal osteoporosis (ibandronate, alendronate, ris...

Medical and Biotech [MESH] Definitions

An aminobisphosphonate derivative of etidronic acid and CALCIUM CHANNEL BLOCKER that inhibits BONE RESORPTION and is used for the treatment of OSTEOPOROSIS.

Monoquaternary homolog of PANCURONIUM. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.

A narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence.

A cholinesterase inhibitor with a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants.

An ADRENERGIC BETA-2 RECEPTOR AGONIST with a prolonged duration of action. It is used to manage ASTHMA and in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

More From BioPortfolio on "A Study to Evaluate and Compare the Effects of Two Approved Drugs in Women With Postmenopausal Osteoporosis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...


Searches Linking to this Trial